Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the need for ongoing provider education about biosimilars.
Transcript:
There is absolutely a need for more educational activities, and we’ll continue to pursue that, both in the medical literature, in reviews, at the major medical meetings, including here at [National Comprehensive Cancer Network, NCCN]. It’s imperative.
However, I've been doing these educational programs probably for the last 3, 3-and-a-half years, and at each one, I do see a more educated audience. When I get the questions about the use of biosimilars that are being asked, they’re clearly more familiar with the concepts, and they're asking more subtle and deeper questions. So I think we are seeing an impact.
Again, we've got NCCN, [the American Society of Clinical Oncology, ASCO], the American Society of Hematology, all doing large educational programs on these, and it's like anything that's new: It takes time. As I said at the beginning, oncologists and hematologists tend to be skeptical of new things. They need to be shown. They need to get some personal experience with it. But I think that's coming, and I think over the next 3 to 5 years, I'm anticipating there will be a large-scale impact of biosimilars.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.